Disc Medicine

IRON · Nasdaq · United States

Share price · IRON

$77.98-2.22 (-2.77%) 3M

close as of 2026-11-18 · 24h delayed · vol 950K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IRON's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 19 Oct 2026+38.9%
  2. 11 Sep 2026-5.5%
  3. 30 Jul 2026+7.5%
  4. 1 Jul 2026+2.5%
  5. 26 Jun 2026+6.6%
  6. 1 Jun 2026+3.4%

    Nothing announced by IRON that day or the session before.

  7. 17 Feb 2026+17.2%
  8. 13 Feb 2026-21.9%
  9. 9 Feb 2026-7.8%

    Nothing announced by IRON that day or the session before.

  10. 27 Jan 2026+5.9%

    Nothing announced by IRON that day or the session before.

Share of unusual movement by asset

For each asset, the share of IRON's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Bitopertin
events and moves
1045%
Selcodebart
events and moves
4shown from 8 days
DISC-3405
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—42%

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
Glycine transporter type 1 (GlyT1)Small molecule
Porphyria
Erythropoietic Protoporphyria
Phase 2
TMPRSS6 (matriptase-2)Monoclonal antibody
Sickle Cell DiseasePolycythemia Vera
Phase 1/2
Hemojuvelin (HJV)Monoclonal antibody
Chronic Kidney DiseaseMyelofibrosis
Anemia of Myelofibrosis

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
SelcodebartPhase 1/2Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis …
Est. primary completion 2027-05 · NCT05320198 · CT.gov ↗
What to watch
July 2027 (1)
DISC-3405Phase 2Polycythemia Vera (PV)
Est. primary completion 2027-07 · NCT06985147 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
BitopertinPhase 2/3Erythropoietic Protoporphyria
Est. primary completion 2028-06 · NCT05883748 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 October 2026Topline resultBitopertinPhase 3 APOLLO of bitopertin in EPP met both co-primary endpoints
Disc Medicine · Source ↗
13 February 2026Complete response letterBitopertinFDA issues complete response letter for the bitopertin NDA in erythropoietic protoporphyria
US, FDA · FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$44M$90M+ $593M short-term inv.$60M-$40M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$47M$99M+ $619M short-term inv.$60M-$44M operating cash flowreport ↗
2026-Q1—$46M$89M+ $641M short-term inv.$64M-$62M operating cash flowreport ↗
2025-Q3—$50M$141M+ $475M short-term inv.$62M-$48M operating cash flowreport ↗
2025-Q2—$46M$128M+ $523M short-term inv.$55M-$48M operating cash flowreport ↗
2025-Q1—$28M$123M+ $572M short-term inv.$34M-$41M operating cash flowreport ↗
2024-Q3—$25M$193M+ $295M short-term inv.$27M-$17M operating cash flowreport ↗
2024-Q2—$23M$281M+ $220M short-term inv.$26M-$15M operating cash flowreport ↗
2024-Q1—$24M$343M$27M-$34M operating cash flowreport ↗
2023-Q3—$14M$371M$14M-$7.5M operating cash flowreport ↗
2023-Q2—$12M$378M$16M-$13M operating cash flowreport ↗
2023-Q1—$20M$237M$23M-$35M operating cash flowreport ↗
2022-Q3—$0.4M$102M$3.3M-$4.0M operating cash flowreport ↗
2022-Q2—$2.6M$109M$7.1M-$9.5M operating cash flowreport ↗
2022-Q1—$9.8M$119M$15M-$16M operating cash flowreport ↗
2021-Q3—$13M$150M$19M-$16M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$171M$91M+ $700M short-term inv.$53M-$180M operating cash flowreport ↗

Disc Medicine reported no revenue disclosure for FY2025. R&D expenses were $170.64M, up 76.5% YoY from $96.67M, and the company ended the year with cash, cash equivalents, and marketable securities of $791.2M, compared to $489.9M at the end of 2024. Full-year net loss was $212.18M.

Management expects existing cash to fund operations into 2029. In the pipeline, the company received a CRL from the FDA for bitopertin in EPP in February 2026; Phase 3 APOLLO enrollment is expected to complete in March 2026 with topline data expected in Q4 2026. Initial Phase 2 data for DISC-0974 in anemia of myelofibrosis were presented at ASH, a Phase 2 IBD study was initiated in Q1 2026, and DISC-3405 studies in polycythemia vera and sickle cell disease are ongoing with data expected in 2H 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$97M$193M+ $297M short-term inv.$27M-$94M operating cash flowreport ↗
2023-FY—$69M$361M+ $0 short-term inv.$19M-$73M operating cash flowreport ↗
2022-FY—$33M$195M$12M-$42M operating cash flowreport ↗
2021-FY—$49M$137M$18M-$60M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 97 sales ($48.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10Savage William Jacob · Chief Medical OfficerOpen-market sale16,035$85.09$1.4MForm 4
2026-10-21Bitterman Kevin · directorOpen-market sale13,783$80.23$1.1MForm 4
2026-10-21Bitterman Kevin · directorOpen-market sale11,470$80.23$920KForm 4
2026-10-21Bitterman Kevin · directorOpen-market sale266$80.23$21KForm 4
2026-10-20Bitterman Kevin · directorOpen-market sale2,869$79.95$229KForm 4
2026-10-20Bitterman Kevin · directorOpen-market sale2,388$79.95$191KForm 4
2026-10-20Bitterman Kevin · directorOpen-market sale55$79.95$4KForm 4
2026-10-19Bitterman Kevin · directorOpen-market sale5,937$79.97$475KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 203 reporting institutions held 41.9M shares ($2.6B, 109.7% of shares outstanding).

#InstitutionSharesValue
1FMR LLC5,586,894$357.2M
2RA CAPITAL MANAGEMENT, L.P.2,450,221$156.7M
3BlackRock, Inc.2,273,831$145.4M
4WELLINGTON MANAGEMENT GROUP LLP1,735,376$111.0M
5STATE STREET CORP1,698,244$108.6M
6Atlas Venture Life Science Advisors, LLC1,513,875$96.8M
7VANGUARD CAPITAL MANAGEMENT LLC1,375,430$87.9M
8Frazier Life Sciences Management, L.P.1,354,852$86.6M
9TCG Crossover Management, LLC1,341,862$85.8M
10JPMORGAN CHASE & CO1,371,480$83.4M
11BVF INC/IL1,272,312$81.4M
12ORBIMED ADVISORS LLC1,067,550$68.3M
13Siren, L.L.C.988,401$63.2M
14Woodline Partners LP958,281$61.3M
15GEODE CAPITAL MANAGEMENT, LLC744,222$47.6M